vimarsana.com

Latest Breaking News On - Hadasit bio - Page 1 : vimarsana.com

AudioCodes : Notice of and Proxy Statement for the Annual General Meeting of Shareholders, dated September 19, 2023 - Form 6-K -September 19, 2023 at 10:35 am EDT

Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy

ALIVE: This is an opportunity to strengthen ties between our countries

ALIVE: This is an opportunity to strengthen ties between our countries Filed on June 10, 2021 The fund has strategic partnerships with Maccabi Health Services, the Assuta Medical Centers chain, the Maccabi Fund, Leumi Partners, as well as British and American firms Professor Rafi Beyar, one of the managing general partners of the ALIVE Israel HealthTech Fund, who took part in the Global Investment Forum in the United Arab Emirates, which was sponsored by The Jerusalem Post and the Khaleej Times, the leading media group in the UAE said: This is an extraordinary opportunity to strengthen bilateral ties between the two countries, said The fund has strategic partnerships with Maccabi Healthcare Services, the Assuta Medical Center network, the Maccabi Fund, Leumi Partners, the British investment group CBG and Carilion Clinic, an American healthcare organization.

Immuno-oncology startup KAHR to work with Philadelphia university on new drugs

Illustrative image of cancer cells (Design Cells; iStock by Getty Images) KAHR, a maker of cancer immunotherapies, said it has entered into an exclusive licensing agreement with Thomas Jefferson University in Philadelphia to develop and commercialize a number of new cancer drug candidates. Under the agreement, the university is granting KAHR the license to develop and commercialize new immuno-oncology drug candidates based on fusion proteins. These drugs are complex structures made by fusing the natural sequence of different proteins to make them bind two or three targets on cancer and immune cells. The new drug candidates entering development are called DSP502 (TIGITxPD1) and DSP216 (LILRB2xSIRPa).

Lineage Cell Therapeutics, Inc (LCTX) Q4 2020 Earnings Call Transcript

Operator Ladies and gentlemen, welcome to the Lineage Cell Therapeutics fourth-quarter and year-end 2020 conference call. [Operator instructions] An audio webcast of this call is available on the Investors section of Lineage s website at www.lineagecell.com. This call is subject to copyright and is property of Lineage. And recordings, reproduction or transmission of this call without expressed written consent of Lineage are strictly prohibited. As a reminder, today s call is being recorded. I would now like to introduce your host for today s conference, Ioana Hone, director of investor relations at Lineage. Ms. Hone, please go ahead. Ioana Hone Director of Investor Relations

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.